Cargando…
Is remdesivir safe in patients with renal impairment? Experience at a large tertiary urban medical center
PURPOSE: Remdesivir is FDA-approved for treatment of patients hospitalized with COVID-19 pneumonia, but not recommended in patients with severe renal failure. This study aims to evaluate the safety of remdesivir in this patient population. METHODS: This was a single-center, retrospective cohort stud...
Autores principales: | Sunny, Subin, Samaroo-Campbell, Jevon, Abdallah, Marie, Luka, Alla, Quale, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132747/ https://www.ncbi.nlm.nih.gov/pubmed/35616879 http://dx.doi.org/10.1007/s15010-022-01850-7 |
Ejemplares similares
-
The initial and lingering impact of coronavirus disease 2019 (COVID-19) on catheter-associated infections in a large healthcare system in New York City
por: Samaroo-Campbell, Jevon, et al.
Publicado: (2022) -
Multi-drug resistant Pseudomonas aeruginosa: a 2019–2020 single center retrospective case control study
por: Yang, Ann Fan, et al.
Publicado: (2023) -
Comparison of Tocilizumab vs Baricitinib in Clinical Outcomes Among Hospitalized Patients With COVID-19: Experience From a Public Hospital System in New York City
por: Sunny, Subin, et al.
Publicado: (2023) -
Carbapenem-Resistant Klebsiella pneumoniae in Large Public Acute-Care Healthcare System, New York, New York, USA, 2016–2022
por: Lee, Jennifer, et al.
Publicado: (2023) -
Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies
por: Kaminski, Monica A., et al.
Publicado: (2020)